These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 31133590)

  • 41. The clinical and economic burden of pneumonia in patients enrolled in Medicare receiving dialysis: a retrospective, observational cohort study.
    Sibbel S; Sato R; Hunt A; Turenne W; Brunelli SM
    BMC Nephrol; 2016 Dec; 17(1):199. PubMed ID: 27955633
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prevalence and direct medical costs of end-stage renal disease in patients with type 2 diabetes mellitus in Switzerland for 2001.
    Sandoz MS; Ess SM; Keusch GW; Schwenkglenks M; Szucs TD
    Swiss Med Wkly; 2004 Aug; 134(31-32):448-58. PubMed ID: 15389348
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cost analysis of renal replacement therapy by transplant in a system of bundled payment of dialysis.
    Rocha MJ; Ferreira S; Martins LS; Almeida M; Dias L; Pedroso S; Henriques AC; Almeida R; Cabrita A
    Clin Transplant; 2012; 26(4):529-31. PubMed ID: 22211715
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cost calculations during "dire straits": a cost-of-illness analysis of regular hemodialysis for end-stage renal disease in Greece.
    Naoum P; Topkaroglou I; Kitsonis D; Skroumpelos A; Athanasakis K; Iatrou C; Boletis J; Kyriopoulos J
    Int J Artif Organs; 2016 Feb; 39(2):87-9. PubMed ID: 26953901
    [TBL] [Abstract][Full Text] [Related]  

  • 45. PD vs HD in Post-Economic Crisis Greece-Differences in Patient Characteristics and Estimation of Therapy Cost.
    Koukou MG; Smyrniotis VE; Arkadopoulos NF; Grapsa EI
    Perit Dial Int; 2017; 37(5):568-573. PubMed ID: 28698249
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cluster analysis and its application to healthcare claims data: a study of end-stage renal disease patients who initiated hemodialysis.
    Liao M; Li Y; Kianifard F; Obi E; Arcona S
    BMC Nephrol; 2016 Mar; 17():25. PubMed ID: 26936756
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Economic burden and cost-utility analysis of three renal replacement therapies in ESRD patients from Yunnan Province, China.
    Wu H; Li Q; Cai Y; Zhang J; Cui W; Zhou Z
    Int Urol Nephrol; 2020 Mar; 52(3):573-579. PubMed ID: 32009220
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Global differences in dialysis modality mix: the role of patient characteristics, macroeconomics and renal service indicators.
    van de Luijtgaarden MW; Jager KJ; Stel VS; Kramer A; Cusumano A; Elliott RF; Geue C; MacLeod AM; Stengel B; Covic A; Caskey FJ
    Nephrol Dial Transplant; 2013 May; 28(5):1264-75. PubMed ID: 23543592
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The economic impact of improving phosphate binder therapy adherence and attainment of guideline phosphorus goals in hemodialysis patients: a Medicare cost-offset model.
    Ramakrishnan K; Braunhofer P; Newsome B; Lubeck D; Wang S; Deuson J; Claxton AJ
    Adv Ther; 2014 Dec; 31(12):1272-86. PubMed ID: 25479935
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The cost of caring for end-stage kidney disease patients: an analysis based on hospital financial transaction records.
    Bruns FJ; Seddon P; Saul M; Zeidel ML
    J Am Soc Nephrol; 1998 May; 9(5):884-90. PubMed ID: 9596087
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Analysis of economic impact between the modality of renal replacement therapy.
    Gouveia DSES; Bignelli AT; Hokazono SR; Danucalov I; Siemens TA; Meyer F; Santos LS; Martins ZCL; Mierzwa TC; Furquim R
    J Bras Nefrol; 2017; 39(2):162-171. PubMed ID: 28489179
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Budget Impact Analysis of Peritoneal Dialysis versus Conventional In-Center Hemodialysis in Malaysia.
    Bavanandan S; Ahmad G; Teo AH; Chen L; Liu FX
    Value Health Reg Issues; 2016 May; 9():8-14. PubMed ID: 27881266
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Gaining efficiencies: resources and demand for dialysis around the globe.
    Neil N; Walker DR; Sesso R; Blackburn JC; Tschosik EA; Sciaraffia V; García-Contreras F; Capsa D; Bhattacharyya SK
    Value Health; 2009; 12(1):73-9. PubMed ID: 18680485
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cost analysis of the Spanish renal replacement therapy programme.
    Villa G; Rodríguez-Carmona A; Fernández-Ortiz L; Cuervo J; Rebollo P; Otero A; Arrieta J
    Nephrol Dial Transplant; 2011 Nov; 26(11):3709-14. PubMed ID: 21427072
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Healthcare costs of patients on different renal replacement modalities - Analysis of Dutch health insurance claims data.
    Mohnen SM; van Oosten MJM; Los J; Leegte MJH; Jager KJ; Hemmelder MH; Logtenberg SJJ; Stel VS; Hakkaart-van Roijen L; de Wit GA
    PLoS One; 2019; 14(8):e0220800. PubMed ID: 31415578
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Costs and added value of haemodialysis and peritoneal dialysis outsourcing agreements.
    Lamas Barreiro JM; Alonso Suárez M; Saavedra Alonso JA; Gándara Martínez A
    Nefrologia; 2011; 31(6):656-63. PubMed ID: 22130280
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Economic impact of extended time on peritoneal dialysis as a result of using polyglucose: the application of a Markov chain model to forecast changes in the development of the ESRD programme over time.
    Weijnen TJ; van Hamersvelt HW; Just PM; Struijk DG; Tjandra YI; ter Wee PM; de Charro FT
    Nephrol Dial Transplant; 2003 Feb; 18(2):390-6. PubMed ID: 12543897
    [TBL] [Abstract][Full Text] [Related]  

  • 58. All-cause costs increase exponentially with increased chronic kidney disease stage.
    Golestaneh L; Alvarez PJ; Reaven NL; Funk SE; McGaughey KJ; Romero A; Brenner MS; Onuigbo M
    Am J Manag Care; 2017 Jun; 23(10 Suppl):S163-S172. PubMed ID: 28978205
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [The cost of dialysis and kidney transplantation in France in 2007, impact of an increase of peritoneal dialysis and transplantation].
    Blotière PO; Tuppin P; Weill A; Ricordeau P; Allemand H
    Nephrol Ther; 2010 Jul; 6(4):240-7. PubMed ID: 20554257
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impact of secondary hyperparathyroidism on disease progression, healthcare resource utilization and costs in pre-dialysis CKD patients.
    Schumock GT; Andress D; E Marx S; Sterz R; Joyce AT; Kalantar-Zadeh K
    Curr Med Res Opin; 2008 Nov; 24(11):3037-48. PubMed ID: 18826748
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.